Amalgamated Bank Grows Holdings in Ionis Pharmaceuticals, Inc. (NASDAQ:IONS)

Amalgamated Bank boosted its holdings in shares of Ionis Pharmaceuticals, Inc. (NASDAQ:IONS) by 3.1% during the 3rd quarter, according to its most recent 13F filing with the SEC. The fund owned 9,957 shares of the company’s stock after purchasing an additional 300 shares during the period. Amalgamated Bank’s holdings in Ionis Pharmaceuticals were worth $399,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently bought and sold shares of the business. Teachers Retirement System of The State of Kentucky grew its holdings in shares of Ionis Pharmaceuticals by 70.6% during the first quarter. Teachers Retirement System of The State of Kentucky now owns 24,083 shares of the company’s stock worth $1,044,000 after buying an additional 9,965 shares during the last quarter. Edgestream Partners L.P. purchased a new position in shares of Ionis Pharmaceuticals in the 1st quarter valued at approximately $765,000. Blair William & Co. IL increased its holdings in shares of Ionis Pharmaceuticals by 67.4% in the first quarter. Blair William & Co. IL now owns 27,838 shares of the company’s stock valued at $1,207,000 after purchasing an additional 11,210 shares during the period. Tidal Investments LLC purchased a new stake in shares of Ionis Pharmaceuticals during the first quarter worth approximately $885,000. Finally, Great Point Partners LLC purchased a new stake in shares of Ionis Pharmaceuticals during the second quarter worth approximately $15,728,000. 93.86% of the stock is currently owned by institutional investors and hedge funds.

Analyst Ratings Changes

IONS has been the topic of several recent research reports. Leerink Partnrs raised shares of Ionis Pharmaceuticals from a “hold” rating to a “strong-buy” rating in a research note on Wednesday, July 24th. StockNews.com cut shares of Ionis Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Tuesday, November 12th. Leerink Partners raised Ionis Pharmaceuticals from a “market perform” rating to an “outperform” rating and lifted their price objective for the company from $53.00 to $62.00 in a report on Wednesday, July 24th. JPMorgan Chase & Co. increased their target price on Ionis Pharmaceuticals from $50.00 to $55.00 and gave the stock a “neutral” rating in a research note on Monday, August 26th. Finally, Barclays raised their price target on Ionis Pharmaceuticals from $45.00 to $51.00 and gave the company an “equal weight” rating in a report on Friday, August 2nd. Two investment analysts have rated the stock with a sell rating, five have issued a hold rating, twelve have issued a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $60.65.

Insiders Place Their Bets

In related news, CEO Brett P. Monia sold 6,630 shares of Ionis Pharmaceuticals stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $38.05, for a total transaction of $252,271.50. Following the completion of the sale, the chief executive officer now owns 167,393 shares in the company, valued at approximately $6,369,303.65. This trade represents a 3.81 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through this hyperlink. Also, EVP Eric Swayze sold 1,194 shares of the company’s stock in a transaction dated Tuesday, November 12th. The shares were sold at an average price of $37.92, for a total transaction of $45,276.48. Following the completion of the transaction, the executive vice president now owns 33,713 shares in the company, valued at approximately $1,278,396.96. This trade represents a 3.42 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 8,197 shares of company stock worth $315,310. Insiders own 2.71% of the company’s stock.

Ionis Pharmaceuticals Price Performance

Ionis Pharmaceuticals stock opened at $34.34 on Friday. The firm has a market capitalization of $5.42 billion, a PE ratio of -14.07 and a beta of 0.39. Ionis Pharmaceuticals, Inc. has a 52 week low of $34.24 and a 52 week high of $54.44. The firm’s 50-day simple moving average is $39.62 and its 200 day simple moving average is $42.76. The company has a quick ratio of 8.82, a current ratio of 8.91 and a debt-to-equity ratio of 1.86.

About Ionis Pharmaceuticals

Ionis Pharmaceuticals, Inc discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an antisense injection for the treatment of polyneuropathy caused by hereditary transthyretin amyloidosis in adults; and WAYLIVRA, an antisense medicine for treatment for familial chylomicronemia syndrome (FCS) and familial partial lipodystrophy.